Abstract 1928P
Background
Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas (incidence 0.15 and 0.51/106/year respectively, PMID: 33630918) with close/similar translocations whose natural history and optimal treatment are not well known. We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010.
Methods
NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB). Since 2010, pathological review is mandatory for sarcoma patients and patients’ characteristics are collected in the NETSARC+ nationwide database. The characteristics of patients with SEF and LGFMS and their outcome are presented and compared.
Results
35/73 (47.9%) and 125/257(48,8%) of patients with SEF and LGFMS were female. More primary visceral, bone and trunk primary sites were observed in SEF (p<0.001). 30.1% of SEF vs 4.3% of LGFMS were metastatic at diagnosis (p<0.0001). Median size of the primary tumor was 51mm (range 10-90). For LGFMS vs 80mm (20-320) for SEF (p<0.001). Median age of LGFMS was 12 years younger than that of SEF (43 [range 4-98] vs 55 [range 10-91], p<0.001). Neoadjuvant treatment was more often given to SEF (16.4% vs 8.6%, p=0.05). More patients with LGFMS were operated first in reference centers (51% vs 26%, p<0.001).The R0 rate was 41% in LGFMS vs 16% in SEF (p<0.001). Median PFS of SEF and LGFMS were 32 and 136 months (p<0.0001) respectively. The median OS was not reached. 50-months OS was 92.6% vs 81% fr SEF (p=0.05). Median survival was 77 months after first relapse, similar for SEF and LGFMS. In multivariate analysis for PFS, SEF histotype, size of the tumor, met at diagnosis were independently correlated to survival. In multivariate analysis for OS, age, size of the tumor, met at diagnosis, but not SEF, independently correlated to survival.
Conclusions
Although sharing close molecular alterations, SEF and LGFMS have a very different natural history, clinical presentation and outcome with a higher risk of metastatic relapse in SEF. Survival after relapse is longer than with other sarcomas, and similar for SEF and LGFMS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Leon Bérard for NETSARC+ Network.
Funding
NetSARC+ (INCA & DGOS) and RREPS (INCA & DGOS), RESOS (INCA & DGOS), LYRICAN+ (INCA-DGOS-INSERM 12563), Eurosarc (FP7-278742), InterSARC (INCA), LabEx DEvweCAN (ANR-10-LABX-0061), EURACAN (EC 739521), Association DAM’s, la Fondation ARC, Infosarcome, Ligue de L’Ain contre le Cancer, La Ligue contre le Cancer funded this study.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15